De Bona A - Search Results

1

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.

Soria A, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'Ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degasperi E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti-Foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, Viganò M, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Fagiuoli S. Soria A, et al. Among authors: de bona a. Liver Int. 2020 Apr;40(4):769-777. doi: 10.1111/liv.14386. Epub 2020 Feb 3. Liver Int. 2020. PMID: 31970845

2

Recombinant interferon-alpha therapy and meno-metrorrhagia.

Uberti-Foppa C, Finazzi R, De Bona A. Uberti-Foppa C, et al. Among authors: de bona a. Br J Obstet Gynaecol. 1998 Mar;105(3):367-8. doi: 10.1111/j.1471-0528.1998.tb10104.x. Br J Obstet Gynaecol. 1998. PMID: 9533004 No abstract available.

3

Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.

Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A. Uberti-Foppa C, et al. Among authors: de bona a. J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):146-52. doi: 10.1097/00126334-200306010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12794546 Clinical Trial.

4

Impact of HAART on liver histology of HIV/HCV coinfected patients.

De Bona A, Sitia G, Uberti-Foppa C, Galli L, Ciuffreda D, Gallotta G, Paties C, Lazzarin A. De Bona A, et al. J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):195-7. J Biol Regul Homeost Agents. 2003. PMID: 14518723

5

Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels.

Uberti-Foppa C, De Bona A, Galli L, Sitia G, Gallotta G, Sagnelli C, Paties C, Lazzarin A. Uberti-Foppa C, et al. Among authors: de bona a. J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):63-7. doi: 10.1097/01.qai.0000192001.15777.15. J Acquir Immune Defic Syndr. 2006. PMID: 16340475

6

Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy.

Sitia G, De Bona A, Bagaglio S, Galli L, Paties CT, Uberti-Foppa C, Guidotti LG, Lazzarin A, Morsica G. Sitia G, et al. Among authors: de bona a. Antivir Ther. 2006;11(3):385-9. Antivir Ther. 2006. PMID: 16759056

7

Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.

Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A. Seminari E, et al. Among authors: de bona a. J Antimicrob Chemother. 2007 Oct;60(4):831-6. doi: 10.1093/jac/dkm282. Epub 2007 Aug 7. J Antimicrob Chemother. 2007. PMID: 17684056

8

Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.

De Bona A, Galli L, Gallotta G, Guzzo A, Alagna L, Lazzarin A, Uberti-Foppa C. De Bona A, et al. New Microbiol. 2007 Jul;30(3):259-64. New Microbiol. 2007. PMID: 17802905 Free article.

9

Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.

Spagnuolo V, Gentilini G, De Bona A, Galli L, Uberti-Foppa C, Soldarini A, Dorigatti F, Seminari E. Spagnuolo V, et al. Among authors: de bona a. New Microbiol. 2007 Jul;30(3):279-82. New Microbiol. 2007. PMID: 17802909 Free article.

10

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data.

Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it. Marcellusi A, et al. Pharmacoeconomics. 2019 Feb;37(2):255-266. doi: 10.1007/s40273-018-0733-3. Pharmacoeconomics. 2019. PMID: 30378086

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters